Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort

Background and Aims: The IL-12/23 inhibitor ustekinumab (UST) opened up new treatment options for patients with Crohn’s disease (CD). Due to the recent approval, real-world German data on long-term efficacy and safety are lacking. This study aimed to assess the clinical course of CD patients under U...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Med
Hlavní autoři: Kubesch, Alica, Rueter, Laurenz, Farrag, Karima, Krause, Thomas, Stienecker, Klaus, Hausmann, Johannes, Filmann, Natalie, Dignass, Axel, Stein, Jürgen, Blumenstein, Irina
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947251/
https://ncbi.nlm.nih.gov/pubmed/31817134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8122140
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky